Page last updated: 2024-10-27

flutamide and Amyotrophic Lateral Sclerosis

flutamide has been researched along with Amyotrophic Lateral Sclerosis in 1 studies

Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.

Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)

Research Excerpts

ExcerptRelevanceReference

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
McLeod, VM1
Lau, CL1
Chiam, MDF1
Rupasinghe, TW1
Roessner, U1
Djouma, E1
Boon, WC1
Turner, BJ1

Other Studies

1 other study available for flutamide and Amyotrophic Lateral Sclerosis

ArticleYear
Androgen receptor antagonism accelerates disease onset in the SOD1
    British journal of pharmacology, 2019, Volume: 176, Issue:13

    Topics: Amyotrophic Lateral Sclerosis; Androgen Receptor Antagonists; Animals; Disease Models, Animal; Disea

2019